Humacyte Shares Are Continuing Higher After the Company on Monday Announced It Was Granted Regenerative Medicine Advanced Therapy Designation by the FDA for Patients With Advanced Peripheral Artery Disease.
Humacyte Shares Are Continuing Higher After the Company on Monday Announced It Was Granted Regenerative Medicine Advanced Therapy Designation by the FDA for Patients With Advanced Peripheral Artery Disease.
在週一宣佈獲得FDA授予的再生醫學先進治療設計用於治療晚期外周動脈疾病患者後，Humacyte的股票持續上漲。
Humacyte Shares Are Continuing Higher After the Company on Monday Announced It Was Granted Regenerative Medicine Advanced Therapy Designation by the FDA for Patients With Advanced Peripheral Artery Disease.
在週一宣佈獲得FDA授予的再生醫學先進治療設計用於治療晚期外周動脈疾病患者後，Humacyte的股票持續上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。